' 
![]()
SCIENTIFIC SCORE
Likely Ineffective
Based on 2 Researches
3
USERS' SCORE
Good
Based on 2 Reviews
8.6
Supplement Facts
Serving Size: 1 Tablet
Amount Per Serving
%DV
Vitamin B₁₂ (as Methylcobalamin)
1,000 mcg
41,667%
Top Medical Research Studies
4
Vitamin B12 shows no heart attack benefit
Urinary excretion of homocysteine thiolactone and the risk of acute myocardial infarction in coronary artery disease patients: the WENBIT trial.
Limited relevance due to findings.
In a recent study, we delved into the role of homocysteine thiolactone, a metabolite linked to heart disease, in predicting the risk of acute myocardial infarction (AMI). Conducted with a sizable group of 2049 patients suspected of having coronary artery disease (CAD), the trial was meticulously designed as a double-blind clinical intervention.
Participants were divided randomly into four distinct groups, receiving a combination of folic acid and other B vitamins or a placebo. Notably, we measured urinary levels of homocysteine thiolactone at different points throughout the study to draw correlations with heart attack incidents.
Our analysis revealed that while the homocysteine thiolactone/creatinine ratio was a significant predictor of AMI risk, there was no observable effect from the vitamin B treatments received by participants. This suggests that vitamin B12, when part of a group of B vitamins, did not independently influence the likelihood of having a heart attack.
Ultimately, we found that higher levels of homocysteine thiolactone correlated with a greater risk of AMI, but the combination of vitamin B treatments did not alter this outcome. This points to the potential of homocysteine thiolactone as an important marker in understanding cardiovascular health.
Participants were divided randomly into four distinct groups, receiving a combination of folic acid and other B vitamins or a placebo. Notably, we measured urinary levels of homocysteine thiolactone at different points throughout the study to draw correlations with heart attack incidents.
Our analysis revealed that while the homocysteine thiolactone/creatinine ratio was a significant predictor of AMI risk, there was no observable effect from the vitamin B treatments received by participants. This suggests that vitamin B12, when part of a group of B vitamins, did not independently influence the likelihood of having a heart attack.
Ultimately, we found that higher levels of homocysteine thiolactone correlated with a greater risk of AMI, but the combination of vitamin B treatments did not alter this outcome. This points to the potential of homocysteine thiolactone as an important marker in understanding cardiovascular health.
Read More
2
Vitamin B12 ineffective for heart attack
Homocysteine thiolactone contributes to the prognostic value of fibrin clot structure/function in coronary artery disease.
Combination therapy's impact unclear
We explored the role of vitamin B12 in relation to heart attacks by examining the effects of a combination therapy including B-vitamins and folate in patients with coronary artery disease (CAD). In a large-scale study involving nearly 2,000 participants, the researchers monitored how these vitamins impacted fibrin clot characteristics and the risk of heart attack over several years.
Surprisingly, our findings indicated that vitamin B12 alone, as part of the combination therapy, did not significantly influence heart attack risk or outcomes. Instead, other factors like homocysteine thiolactone and plasma cysteine emerged as key players in determining clot properties and predicting adverse outcomes.
While we noted that baseline clot lysis time and maximum absorbance were associated with higher risks of acute myocardial infarction and mortality, the treatment with B-vitamins did not alter these markers significantly. Thus, the lack of efficacy from vitamin B12 in this context raises important questions about its effectiveness in preventing heart attacks when administered with other nutrients.
Surprisingly, our findings indicated that vitamin B12 alone, as part of the combination therapy, did not significantly influence heart attack risk or outcomes. Instead, other factors like homocysteine thiolactone and plasma cysteine emerged as key players in determining clot properties and predicting adverse outcomes.
While we noted that baseline clot lysis time and maximum absorbance were associated with higher risks of acute myocardial infarction and mortality, the treatment with B-vitamins did not alter these markers significantly. Thus, the lack of efficacy from vitamin B12 in this context raises important questions about its effectiveness in preventing heart attacks when administered with other nutrients.
Read More
Most Useful Reviews
8.8
Enhances cardiovascular health
This supplement is beneficial for the nervous system and supports the brain and spinal cord. It helps the cardiovascular system by preventing thrombus formation, reducing the risk of atherosclerosis, heart attack, and stroke, while also normalising blood pressure.
Read More
8.8
Supports heart health
I discovered a deficiency in vitamin B12 and chose this supplement due to its excellent composition and convenient chewable form. It dissolves under my tongue, and the lemon flavour is delightful. My doctor recommended it as B12 aids in reducing homocysteine levels, which protects the heart, supports blood cell formation, and is essential for the nervous system. I've been taking it for a month on an empty stomach, feel well, and have no side effects. I'll retest in a month.
Read More
Medical Researches
SCIENTIFIC SCORE
Likely Ineffective
Based on 2 Researches
3
4
Vitamin B12 shows no heart attack benefit
Urinary excretion of homocysteine thiolactone and the risk of acute myocardial infarction in coronary artery disease patients: the WENBIT trial.
Limited relevance due to findings.
In a recent study, we delved into the role of homocysteine thiolactone, a metabolite linked to heart disease, in predicting the risk of acute myocardial infarction (AMI). Conducted with a sizable group of 2049 patients suspected of having coronary artery disease (CAD), the trial was meticulously designed as a double-blind clinical intervention.
Participants were divided randomly into four distinct groups, receiving a combination of folic acid and other B vitamins or a placebo. Notably, we measured urinary levels of homocysteine thiolactone at different points throughout the study to draw correlations with heart attack incidents.
Our analysis revealed that while the homocysteine thiolactone/creatinine ratio was a significant predictor of AMI risk, there was no observable effect from the vitamin B treatments received by participants. This suggests that vitamin B12, when part of a group of B vitamins, did not independently influence the likelihood of having a heart attack.
Ultimately, we found that higher levels of homocysteine thiolactone correlated with a greater risk of AMI, but the combination of vitamin B treatments did not alter this outcome. This points to the potential of homocysteine thiolactone as an important marker in understanding cardiovascular health.
Participants were divided randomly into four distinct groups, receiving a combination of folic acid and other B vitamins or a placebo. Notably, we measured urinary levels of homocysteine thiolactone at different points throughout the study to draw correlations with heart attack incidents.
Our analysis revealed that while the homocysteine thiolactone/creatinine ratio was a significant predictor of AMI risk, there was no observable effect from the vitamin B treatments received by participants. This suggests that vitamin B12, when part of a group of B vitamins, did not independently influence the likelihood of having a heart attack.
Ultimately, we found that higher levels of homocysteine thiolactone correlated with a greater risk of AMI, but the combination of vitamin B treatments did not alter this outcome. This points to the potential of homocysteine thiolactone as an important marker in understanding cardiovascular health.
Read More
2
Vitamin B12 ineffective for heart attack
Homocysteine thiolactone contributes to the prognostic value of fibrin clot structure/function in coronary artery disease.
Combination therapy's impact unclear
We explored the role of vitamin B12 in relation to heart attacks by examining the effects of a combination therapy including B-vitamins and folate in patients with coronary artery disease (CAD). In a large-scale study involving nearly 2,000 participants, the researchers monitored how these vitamins impacted fibrin clot characteristics and the risk of heart attack over several years.
Surprisingly, our findings indicated that vitamin B12 alone, as part of the combination therapy, did not significantly influence heart attack risk or outcomes. Instead, other factors like homocysteine thiolactone and plasma cysteine emerged as key players in determining clot properties and predicting adverse outcomes.
While we noted that baseline clot lysis time and maximum absorbance were associated with higher risks of acute myocardial infarction and mortality, the treatment with B-vitamins did not alter these markers significantly. Thus, the lack of efficacy from vitamin B12 in this context raises important questions about its effectiveness in preventing heart attacks when administered with other nutrients.
Surprisingly, our findings indicated that vitamin B12 alone, as part of the combination therapy, did not significantly influence heart attack risk or outcomes. Instead, other factors like homocysteine thiolactone and plasma cysteine emerged as key players in determining clot properties and predicting adverse outcomes.
While we noted that baseline clot lysis time and maximum absorbance were associated with higher risks of acute myocardial infarction and mortality, the treatment with B-vitamins did not alter these markers significantly. Thus, the lack of efficacy from vitamin B12 in this context raises important questions about its effectiveness in preventing heart attacks when administered with other nutrients.
Read More
User Reviews
USERS' SCORE
Good
Based on 2 Reviews
8.6
8.8
Supports heart health
I discovered a deficiency in vitamin B12 and chose this supplement due to its excellent composition and convenient chewable form. It dissolves under my tongue, and the lemon flavour is delightful. My doctor recommended it as B12 aids in reducing homocysteine levels, which protects the heart, supports blood cell formation, and is essential for the nervous system. I've been taking it for a month on an empty stomach, feel well, and have no side effects. I'll retest in a month.
Read More
8.8
Enhances cardiovascular health
This supplement is beneficial for the nervous system and supports the brain and spinal cord. It helps the cardiovascular system by preventing thrombus formation, reducing the risk of atherosclerosis, heart attack, and stroke, while also normalising blood pressure.
